Prostate

• 

  Publication Venue For

  • HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer..  79:414-424. 2019
  • SRRM4 gene expression correlates with neuroendocrine prostate cancer..  79:96-104. 2019
  • Germline mutations in PPFIBP2 are associated with lethal prostate cancer..  78:1222-1228. 2018
  • A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer..  78:607-615. 2018
  • Rare germline mutations in African American men diagnosed with early-onset prostate cancer..  78:321-326. 2018
  • Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer..  78:266-277. 2018
  • Genetic factors influencing prostate cancer risk in Norwegian men..  78:186-192. 2018
  • Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients..  78:17-24. 2018
  • Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.  77:385-395. 2017
  • Is PSA related to serum cholesterol and does the relationship differ between black and white men?.  75:1877-1885. 2015
  • A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate..  75:1447-1453. 2015
  • Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America..  75:836-844. 2015
  • Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.  75:463-473. 2015
  • Carbohydrate intake, glycemic index and prostate cancer risk..  75:430-439. 2015
  • Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats..  75:381-389. 2015
  • Patient preferences for treatments to delay bone metastases..  74:1488-1497. 2014
  • Mutational landscape of candidate genes in familial prostate cancer..  74:1371-1378. 2014
  • Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer..  74:983-990. 2014
  • Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.  73:1378-1390. 2013
  • Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database..  73:409-417. 2013
  • Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways.  73:754-762. 2013
  • The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model.  73:449-454. 2013
  • PDEF in prostate cancer..  72:592-596. 2012
  • Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG..  72:410-426. 2012
  • Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences..  72:173-180. 2012
  • Early onset prostate cancer has a significant genetic component..  72:147-156. 2012
  • Emerging treatment options for patients with castration-resistant prostate cancer..  72:338-349. 2012
  • PC3 is a cell line characteristic of prostatic small cell carcinoma.  71:1668-1679. 2011
  • Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy..  71:1492-1498. 2011
  • Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study..  71:225-231. 2011
  • Glycemic control and prostate cancer progression: results from the SEARCH database..  70:1540-1546. 2010
  • Effect of intermittent fasting with or without caloric restriction on prostate cancer growth and survival in SCID mice..  70:1037-1043. 2010
  • Racial differences in prostate cancer risk remain among US servicemen with equal access to care..  70:727-734. 2010
  • Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men..  69:956-960. 2009
  • Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.  69:787-798. 2009
  • Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients..  69:520-527. 2009
  • Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23..  69:385-391. 2009
  • The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer..  69:142-148. 2009
  • ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells..  68:1273-1282. 2008
  • Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy..  68:1380-1386. 2008
  • Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.  68:839-848. 2008
  • Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer..  68:675-678. 2008
  • Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study..  68:296-305. 2008
  • Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis..  68:11-19. 2008
  • Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer..  67:1507-1513. 2007
  • Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC)..  67:22-31. 2007
  • Immunohistochemical characterization of neuroendocrine cells in prostate cancer.  66:1399-1406. 2006
  • Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project..  66:173-179. 2006
  • INSPstI polymorphism and prostate cancer in African-American men..  65:83-87. 2005
  • Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families..  64:60-66. 2005
  • Explaining racial differences in prostate cancer in the United States: sociology or biology?.  62:243-252. 2005
  • Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB..  61:105-113. 2004
  • Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1..  57:326-334. 2003
  • Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer..  55:71-80. 2003
  • R726L androgen receptor mutation is uncommon in prostate cancer families in the united states..  54:306-309. 2003
  • Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth..  54:315-321. 2003
  • Relationship of serum sex-steroid hormones and prostate volume in African American men..  53:322-329. 2002
  • Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells..  53:200-210. 2002
  • Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate..  51:117-125. 2002
  • Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo..  51:141-152. 2002
  • Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin..  48:71-78. 2001
  • Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study..  47:269-275. 2001
  • Rational basis for Trk inhibition therapy for prostate cancer..  45:140-148. 2000
  • Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers..  42:295-303. 2000
  • Mutational analysis of the TrkA gene in prostate cancer..  36:172-180. 1998
  • Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes..  33:55-59. 1997
  • Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens..  32:59-64. 1997
  • Mutations of the p16 gene product are rare in prostate cancer..  30:188-194. 1997
  • 6-Methylene progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity..  26:28-34. 1995
  • A coaxial microwave applicator for transurethral hyperthermia of the prostate..  22:125-138. 1993
  • Infrequent RAS oncogene mutations in human prostate cancer..  20:327-338. 1992
  • Establishment of a long‐term adenocarcinoma of the prostate cell line in the nude mouse.  7:369-376. 1985
  • A serologic approach to the definition of human prostatic carcinoma antigens..  2:369-380. 1981